{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:06:34Z","timestamp":1786975594995,"version":"build-2736575974"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2020,11,1]]},"DOI":"10.1001\/jamadermatol.2020.2977","type":"journal-article","created":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T11:01:57Z","timestamp":1599649317000},"page":"1208","source":"Crossref","is-referenced-by-count":95,"title":["Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti\u2013Interleukin 12\/23p40 Antibody Ustekinumab"],"prefix":"10.1001","volume":"156","author":[{"given":"Florence","family":"Poizeau","sequence":"first","affiliation":[{"name":"EA 7449 REPERES (Pharmacoepidemiology and Health Services Research), University of Rennes 1, Rennes, France"},{"name":"PEPS Research Consortium (Pharmacoepidemiology for Health Product Safety), Rennes, France"},{"name":"Department of Dermatology, CHU Rennes, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Nowak","sequence":"additional","affiliation":[{"name":"PEPS Research Consortium (Pharmacoepidemiology for Health Product Safety), Rennes, France"},{"name":"University of Bretagne Occidentale, Brest University, Brest, France"},{"name":"INSERM CIC 1412, CHRU Brest, Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Kerbrat","sequence":"additional","affiliation":[{"name":"EA 7449 REPERES (Pharmacoepidemiology and Health Services Research), University of Rennes 1, Rennes, France"},{"name":"PEPS Research Consortium (Pharmacoepidemiology for Health Product Safety), Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9ranger","family":"Le Nautout","sequence":"additional","affiliation":[{"name":"EA 7449 REPERES (Pharmacoepidemiology and Health Services Research), University of Rennes 1, Rennes, France"},{"name":"PEPS Research Consortium (Pharmacoepidemiology for Health Product Safety), Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Droitcourt","sequence":"additional","affiliation":[{"name":"EA 7449 REPERES (Pharmacoepidemiology and Health Services Research), University of Rennes 1, Rennes, France"},{"name":"PEPS Research Consortium (Pharmacoepidemiology for Health Product Safety), Rennes, France"},{"name":"Department of Dermatology, CHU Rennes, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milou-Daniel","family":"Drici","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, CHU Nice, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Sbidian","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Henri Mondor Hospital, APHP, Cr\u00e9teil, France"},{"name":"EA EpiDermE 7379, Paris Est Cr\u00e9teil University, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Guillot","sequence":"additional","affiliation":[{"name":"Department of Dermatology, CHU Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Bachelez","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, Paris, France"},{"name":"INSERM UMR1163, Institut Imagine, Paris, France"},{"name":"Department of Dermatology, Saint-Louis Hospital, APHP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafid","family":"Ait-Oufella","sequence":"additional","affiliation":[{"name":"INSERM U970, Paris Cardiovascular Research Centre, Universit\u00e9 de Paris, Paris, France"},{"name":"Department of Intensive Care, Saint-Antoine Hospital, APHP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Happe","sequence":"additional","affiliation":[{"name":"EA 7449 REPERES (Pharmacoepidemiology and Health Services Research), University of Rennes 1, Rennes, France"},{"name":"PEPS Research Consortium (Pharmacoepidemiology for Health Product Safety), Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Oger","sequence":"additional","affiliation":[{"name":"EA 7449 REPERES (Pharmacoepidemiology and Health Services Research), University of Rennes 1, Rennes, France"},{"name":"PEPS Research Consortium (Pharmacoepidemiology for Health Product Safety), Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Dupuy","sequence":"additional","affiliation":[{"name":"EA 7449 REPERES (Pharmacoepidemiology and Health Services Research), University of Rennes 1, Rennes, France"},{"name":"PEPS Research Consortium (Pharmacoepidemiology for Health Product Safety), Rennes, France"},{"name":"Department of Dermatology, CHU Rennes, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"doi200049r1","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/ni.2001","article-title":"The immune system in atherosclerosis.","volume":"12","author":"Hansson","year":"2011","journal-title":"Nat Immunol"},{"key":"doi200049r2","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.3389\/fimmu.2018.01668","article-title":"Psoriasis, cardiovascular events, and biologics: lights and shadows.","volume":"9","author":"Caiazzo","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"doi200049r3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/CIRCRESAHA.118.313129","article-title":"Anticytokine agents: targeting interleukin signaling pathways for the treatment of atherothrombosis.","volume":"124","author":"Ridker","year":"2019","journal-title":"Circ Res"},{"issue":"4","key":"doi200049r4","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/cvr\/cvz009","article-title":"Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study.","volume":"115","author":"Elnabawi","year":"2019","journal-title":"Cardiovasc Res"},{"issue":"11","key":"doi200049r5","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1161\/CIRCRESAHA.118.313608","article-title":"Association between oxidation-modified lipoproteins and coronary plaque in psoriasis.","volume":"123","author":"Sorokin","year":"2018","journal-title":"Circ Res"},{"issue":"1","key":"doi200049r6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00281-015-0539-8","article-title":"Update on psoriasis immunopathogenesis and targeted immunotherapy.","volume":"38","author":"Mahil","year":"2016","journal-title":"Semin Immunopathol"},{"issue":"6","key":"doi200049r7","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.117.007394","article-title":"Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial.","volume":"11","author":"Mehta","year":"2018","journal-title":"Circ Cardiovasc Imaging"},{"issue":"1","key":"doi200049r8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jid.2019.07.679","article-title":"A phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U Trial).","volume":"140","author":"Gelfand","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"5","key":"doi200049r9","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1111\/bjd.2017.177.issue-5","article-title":"Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis.","volume":"177","author":"Iskandar","year":"2017","journal-title":"Br J Dermatol"},{"key":"doi200049r10","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.","volume":"12","author":"Sbidian","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"doi200049r11","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1161\/ATVBAHA.110.214585","article-title":"Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-a blockers and traditional disease-modifying antirheumatic drugs.","volume":"31","author":"Di Minno","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"doi200049r12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jaad.2016.07.042","article-title":"Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-a inhibitors versus methotrexate.","volume":"76","author":"Wu","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi200049r13","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/annrheumdis-2016-209784","article-title":"Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis.","volume":"76","author":"Low","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"doi200049r14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.atherosclerosis.2003.10.004","article-title":"Exclusive expression of transmembrane TNF-alpha in mice reduces the inflammatory response in early lipid lesions of aortic sinus.","volume":"172","author":"Canault","year":"2004","journal-title":"Atherosclerosis"},{"issue":"8","key":"doi200049r15","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jama.2011.1211","article-title":"Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.","volume":"306","author":"Ryan","year":"2011","journal-title":"JAMA"},{"issue":"10","key":"doi200049r16","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1084\/jem.20090545","article-title":"Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis.","volume":"206","author":"Taleb","year":"2009","journal-title":"J Exp Med"},{"issue":"196","key":"doi200049r17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006133","article-title":"Transforming growth factor-\u00df signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17\u2013dependent pathway.","volume":"5","author":"Gister\u00e5","year":"2013","journal-title":"Sci Transl Med"},{"issue":"2","key":"doi200049r18","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1161\/ATVBAHA.114.303567","article-title":"IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles.","volume":"35","author":"Taleb","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"doi200049r19","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.immuni.2018.09.011","article-title":"An interleukin-23\u2013interleukin-22 axis regulates intestinal microbial homeostasis to protect from diet-induced atherosclerosis.","volume":"49","author":"Fatkhullina","year":"2018","journal-title":"Immunity"},{"key":"doi200049r20","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: From the Syst\u00e8me National D\u2019information Interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the Syst\u00e8me National des Donn\u00e9es de Sant\u00e9 (SNDS) in France.","volume":"65","author":"Tuppin","year":"2017","journal-title":"Rev Epidemiol Sante Publique"},{"issue":"4","key":"doi200049r21","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/00001648-199807000-00016","article-title":"The case-time-control design: further assumptions and conditions.","volume":"9","author":"Suissa","year":"1998","journal-title":"Epidemiology"},{"issue":"2","key":"doi200049r23","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/oxfordjournals.aje.a115853","article-title":"The case-crossover design: a method for studying transient effects on the risk of acute events.","volume":"133","author":"Maclure","year":"1991","journal-title":"Am J Epidemiol"},{"issue":"11","key":"doi200049r24","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1002\/pds.3508","article-title":"Case-crossover study design in pharmacoepidemiology: systematic review and recommendations.","volume":"22","author":"Consiglio","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"doi200049r25","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/00001648-199505000-00010","article-title":"The case-time-control design.","volume":"6","author":"Suissa","year":"1995","journal-title":"Epidemiology"},{"key":"doi200049r26","first-page":"59","article-title":"Basic problems in interaction assessment.","volume":"101","author":"Greenland","year":"1993","journal-title":"Environ Health Perspect"},{"issue":"5","key":"doi200049r28","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/jdv.2013.27.issue-5","article-title":"Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti\u2013IL-12\/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials.","volume":"27","author":"Tzellos","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"doi200049r29","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2013.01.011","article-title":"Major cardiovascular events associated with anti\u2013IL 12\/23 agents: a tale of two meta-analyses.","volume":"68","author":"Dommasch","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"doi200049r30","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/jdv.2013.27.issue-12","article-title":"Association of anti\u2013IL-12\/23 biologic agents ustekinumab and briakinumab with major adverse cardiovascular events.","volume":"27","author":"Tzellos","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"doi200049r31","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/bjd.2011.164.issue-4","article-title":"Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.","volume":"164","author":"Reich","year":"2011","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi200049r32","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/bjd.14964","article-title":"Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials.","volume":"176","author":"Rungapiromnan","year":"2017","journal-title":"Br J Dermatol"},{"issue":"10","key":"doi200049r33","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCRESAHA.114.302761","article-title":"Adaptive (T and B cells) immunity and control by dendritic cells in atherosclerosis.","volume":"114","author":"Ait-Oufella","year":"2014","journal-title":"Circ Res"},{"issue":"2","key":"doi200049r34","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1161\/ATVBAHA.111.229997","article-title":"Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E\u2013deficient mice.","volume":"32","author":"Danzaki","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"doi200049r35","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.biopha.2018.07.110","article-title":"The pleiotropic role of interleukin-17 in atherosclerosis.","volume":"106","author":"Allam","year":"2018","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"doi200049r36","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1093\/eurheartj\/ehs263","article-title":"Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction.","volume":"34","author":"Simon","year":"2013","journal-title":"Eur Heart J"},{"issue":"6","key":"doi200049r37","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/jdv.12768","article-title":"Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort.","volume":"29","author":"Ahlehoff","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"doi200049r38","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00403-015-1593-8","article-title":"Drug safety of systemic treatments for psoriasis: results from the German Psoriasis Registry PsoBest.","volume":"307","author":"Reich","year":"2015","journal-title":"Arch Dermatol Res"},{"issue":"6","key":"doi200049r39","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1001\/jamadermatol.2019.0001","article-title":"Association of ustekinumab vs TNF inhibitor therapy with risk of atrial fibrillation and cardiovascular events in patients with psoriasis or psoriatic arthritis.","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"4","key":"doi200049r40","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.annepidem.2003.09.012","article-title":"Use of the case-crossover design to study prolonged drug exposures and insidious outcomes.","volume":"14","author":"Wang","year":"2004","journal-title":"Ann Epidemiol"},{"issue":"6","key":"doi200049r41","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/jim.2009.265.issue-6","article-title":"Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study.","volume":"265","author":"Bots","year":"2009","journal-title":"J Intern Med"},{"issue":"10","key":"doi200049r42","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1001\/jamacardio.2018.2769","article-title":"Association between aortic vascular inflammation and coronary artery plaque characteristics in psoriasis.","volume":"3","author":"Joshi","year":"2018","journal-title":"JAMA Cardiol"},{"key":"doi200049r27","volume-title":"Statistical Analysis of Epidemiologic Data","author":"Selvin","year":"1996"},{"key":"doi200049r22","unstructured":"European Commission. Stelara (ustekinumab): annexe 1: r\u00e9sum\u00e9 des caract\u00e9ristiques du produit. Accessed August 5, 2020. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2020\/20200120147051\/anx_147051_fr.pdf"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2770560\/jamadermatology_poizeau_2020_oi_200049_1604610890.24292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T09:34:24Z","timestamp":1617183264000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2770560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,1]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2020.2977","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,1]]}}}